Finance

Lists
Q3 2026 earnings • released • Revenue beat +60.42%
See results
GLUE:NASDAQ
Monte Rosa Therapeutics Inc
$10.25
-5.27%
(-0.57) 1D
$10.25
0.00% (0.00)
After hours
Closed: Nov 5, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GLUE...
Open
$10.48
High
$10.58
Low
$10.13
Mkt. cap
874.46M
Avg. vol.
1.49M
Volume
1.50M
52-wk high
$25.77
52-wk low
$9.68
EPS
-$1.74
Beta
1.41
Shares outstanding
85.31M
No. of employees
173
Open
$10.48
High
$10.58
Low
$10.13
Mkt. cap
874.46M
Avg. vol.
1.49M
Volume
1.50M
52-wk high
$25.77
52-wk low
$9.68
EPS
-$1.74
Beta
1.41
Shares outstanding
85.31M
No. of employees
173
News stories
From web sources and news partners
About Monte Rosa Therapeutics Inc
CEO-
Employees173
Founded2019
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitemonterosatx.com
Analyst ratings
Based on 7 analysts giving stock ratings to GLUE in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for GLUE in the last 3 months.
Highest
Current $10.25
$37.00 (+260.98%)
Average
$27.17 (+165.07%)
Lowest
$19.00 (+85.37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
UBS
Buy
Reiterated
$19.00
+85.4%
10/12/2026
Alice Nettleton
UBS
Buy
Initiated
$19.00
+85.4%
10/12/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$25.00
+143.9%
10/05/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
-
-
10/02/2026
Robert Driscoll
Wedbush
Buy
Maintained
$27.00
+163.4%
10/02/2026
Unknown Analyst
Wedbush
Buy
Maintained
$27.00
+163.4%
10/02/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$28.00
+173.2%
10/01/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$37.00
+261%
10/02/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$27.00
+163.4%
08/10/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$25.00
+143.9%
07/31/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$29.00
+182.9%
06/24/2026
Marc Frahm
TD Cowen
Buy
Reiterated
-
-
05/07/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
- / -$0.20
Revenue / Est. (USD)
54.37M / 33.89M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
12.77M
2.78M
4.21M
8.97M
Cost of goods sold
34.65M
39.89M
41.82M
45.99M
Cost of revenue
34.65M
39.89M
41.82M
45.99M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.09M
12.60M
12.42M
12.11M
Operating expense
11.09M
12.60M
12.42M
12.11M
Total operating expenses
45.74M
52.50M
54.24M
58.10M
Operating income
-32.98M
-49.72M
-50.03M
-49.13M
Other non operating income
-
-
-
-
EBT including unusual items
-30.26M
-46.08M
-44.45M
-43.19M
EBT excluding unusual items
-30.26M
-46.08M
-44.45M
-43.19M
Income tax expense
-3.18M
59.00K
52.00K
208.00K
Effective tax rate
10.50%
-0.13%
-0.12%
-0.48%
Other operating expenses
-
-
-
-
Net income
-27.08M
-46.14M
-44.50M
-43.40M
Net profit margin
-212.10%
-1,658.94%
-1,057.08%
-483.91%
Earnings per share
-0.33
-0.55
-0.45
-0.43
Interest and investment income
2.75M
3.69M
5.59M
5.92M
Interest expense
-
-
-
-
Net interest expenses
2.75M
3.69M
5.59M
5.92M
Depreciation and amortization charges
-
-
-
-
EBITDA
-30.88M
-47.63M
-48.00M
-47.22M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps